The Pharma Data
JANUARY 3, 2021
The information in the press release is information that Nanoform is obliged to make public pursuant to the EU Market Abuse Regulation. This press release contains forward-looking statements, including, without limitation, statements regarding Nanoform’s strategy, business plans and focus. . +46 7686 650 11. 2 Proof of Concept.
The Pharma Data
NOVEMBER 26, 2020
The information in the press release is information that Nanoform is obliged to make public pursuant to the EU Market Abuse Regulation. This press release contains forward-looking statements, including, without limitation, statements regarding Nanoform’s strategy, business plans and focus. Finnish time. About Nanoform.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
The Pharma Data
DECEMBER 3, 2020
Maribavir, an orally bioavailable anti-CMV compound, is the only antiviral agent presently in Phase 3 development for the treatment of post-transplant patients with CMV in SOT or HSCT. In transplant recipients, reactivation of CMV can lead to serious consequences including loss of the transplanted organ and, in extreme cases, can be fatal.
Pharmaceutical Technology
NOVEMBER 24, 2022
This is due to the fact that the current Good Manufacturing Practice (cGMP) standards required for human studies involve a significant investment in infrastructure and quality systems in order to efficiently comply with all national and international regulations. What makes Quotient Sciences’ approach to these study types unique?
Drug Discovery World
OCTOBER 25, 2023
It contains structure-related data for more than 3 million compounds, over 5000 unique animal and human validation datasets, and physiological parameters of 196 different subject populations (different species, gender, strain, sub-strain) and counting.
The Pharma Data
JANUARY 27, 2021
Each study is planned to be carried out over an approximately two-week period as an open label, randomized, crossover, two-period, two-sequence, single dose pilot study to assess the relative bioavailability of each product. SOURCE: XPhyto Therapeutics Corp. View source version on accesswire.com: [link].
Pharmaceutical Technology
MARCH 7, 2023
Safety issues must also be addressed, such as containment and potential ignition factors. Frewitt’s expertise also includes solutions to the API containment space, with both rigid and flexible isolators. [i]
Expert insights. Personalized for you.
52 
Let's personalize your content